ReviewFrontiers in microbiology2019
Recent Advances in Synthetic Biology Approaches to Optimize Production of Bioactive Natural Products in Actinobacteria.
Review in Frontiers in microbiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 52 citations in OpenAlex.
- Multi-Targeting Non-Specific Genome Engineering in Bacteria.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Revitalizing actinobacteria research: an urgent response to the antimicrobial resistance crisis.Natural products and bioprospecting · 2026Article
- Decoding the regulatory role of AmiC in amicoumacins production through transcriptomics and metabolic profiling in Bacillus subtilis fmb60.World journal of microbiology & biotechnology · 2026Article
- Enhancement of Acarbose Production inJournal of agricultural and food chemistry · 2025Article
- Current Approaches and Implications in Discovery of Novel Bioactive Products from Microbial Sources.Current microbiology · 2025Review
- Current Approaches for Genetic Manipulation ofBiotech (Basel (Switzerland)) · 2025Review
- Actinomycetes - The Repertoire of Diverse Bioactive Chemical Molecules: From Structures to Antibiotics.Current topics in medicinal chemistry · 2025Review
- Comparative Genomics and Biosynthetic Cluster Analysis of Antifungal Secondary Metabolites of Three Strains ofMicroorganisms · 2024Article
- Stepwise increase of fidaxomicin in an engineered heterologous hostSynthetic and systems biotechnology · 2024Article
- Harnessing bacterial metabolites for enhanced cancer chemotherapy: unveiling unique therapeutic potentials.Archives of microbiology · 2024Review
- CRISPR/Cas9-Mediated Promoter Engineering in Saccharopolyspora erythraea.Methods in molecular biology (Clifton, N.J.) · 2024Article
- Bioprospecting of Metabolites from Actinomycetes and their Applications.Recent patents on biotechnology · 2024Review
- Expression of blue pigment synthetase a from Streptomyces lavenduale reveals insights on the effects of refactoring biosynthetic megasynthases for heterologous expression in Escherichia coli.Protein expression and purification · 2023Article
- Enhanced production of aspochalasin D through genetic engineering of Aspergillus flavipes.Applied microbiology and biotechnology · 2023Article
- Quantitative characterization of filamentous fungal promoters on a single-cell resolution to discover cryptic natural products.Science China. Life sciences · 2023Article
- Review
- Improvement of Rimocidin Biosynthesis by Increasing Supply of Precursor Malonyl-CoA via Over-expression of Acetyl-CoA Carboxylase in Streptomyces rimosus M527.Current microbiology · 2022Article
- Delineation of mechanistic approaches of rhizosphere microorganisms facilitated plant health and resilience under challenging conditions.3 Biotech · 2022Review
- Droplet-Microfluidic-Based Promoter Engineering and Expression Fine-Tuning for Improved Erythromycin Production inFrontiers in bioengineering and biotechnology · 2022Article
- Genome Sequence-Guided Finding of Lucensomycin Production byMicroorganisms · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Actinobacteria represent one of the most fertile sources for the discovery and development of natural products (NPs) with medicinal and industrial importance. However, production titers of actinobacterial NPs are usually low and require optimization for compound characterization and/or industrial production. In recent years, a wide variety of novel enabling technologies for engineering actinobacteria have been developed, which have greatly facilitated the optimization of NPs biosynthesis. In this review, we summarize the recent advances of synthetic biology approaches for overproducing desired drugs, as well as for the discovery of novel NPs in actinobacteria, including dynamic metabolic regulation based on metabolite-responsive promoters or biosensors, multi-copy chromosomal integration of target biosynthetic gene clusters (BGCs), promoter engineering-mediated rational BGC refactoring, and construction of genome-minimized
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.